AKBA PDUFA decision: a positive outcome, +12.0%

On March 27, 2024, Akebia Therapeutics, Inc. reached its PDUFA decision. The result was a positive outcome, and the stock moved +12.0% in the window around the event. It had already run +43.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.